Read More: https://www.tipranks.com/news/the-fly/boston-scientific-bolt-medical-acquisition-checks-right-boxes-jpmorgan-says?utm_source=alphanewsstream.com&utm_medium=referral
Deeply oversold similar to XLP, but too big an allocation to go long without more evidence of positive change
Healthcare Sector November Outlook—Healthcare stocks are down and out to start November Read More »
Boston Scientific’s target price was increased by Citigroup from $92.00 to $98.00 in a report released on Thursday, as reported by Benzinga. The brokerage firm currently holds a buy rating.
Citigroup increases the price target for Boston Scientific (NYSE:BSX) to $98.00. Read More »
We are near market weight in our XLV allocation for September. Model inputs have improved marginally, but the sustained consolidation in equity prices that typically catalyze performance for the sector have remained elusive
The XLV lost ground by moving sideways in June, unable to entice investors who were looking to add risk instead. The price action has been sideways since XLV peaked in February, and with a weak start to July trading, the pattern is taking on a distributional look.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are looking into the potential acquisition of Silk Road Medical, Inc. (NasdaqGS: SILK) by…
Symbols such as MTUM, CAT, BSX, and ANET are referenced in this story. Exchange traded funds (ETFs) are similar to stocks in that they are traded on the stock market, but investors are purchasing and selling “units” instead of traditional shares.
There has been a significant outflow detected in the notable ETFs MTUM, CAT, BSX, ANET. Read More »
Boston Scientific has acquired Silk Road Medical, a company that produces products to aid in stroke prevention for patients with carotid artery issues.
Boston Scientific has acquired Silk Road Medical for $1.26 billion. Read More »
